TCTMD -- Aspirin therapy has long been an established strategy for secondary prevention of cardiovascular events in patients with type 2 diabetes. But a new study published online June 1, 2010, ahead of print in Circulation, offers evidence that the antiplatelet drug cilostazol may be considerably more effective than aspirin at preventing the progression of atherosclerosis in patients with diabetes.
